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Abstract
Background: Medications may be consumed periconceptionally before a woman knows she is pregnant. In this study, the
authors evaluate the association of a prescription diet drug (Letigen) containing ephedrine (20 mg) and caffeine (200 mg)
with spontaneous abortion (SAB) in the Danish National Birth Cohort.
Methods: Women were recruited during their first prenatal visit from 1996–2002. Pre-conception and early pregnancy
medication use was reported on the enrollment form, and pregnancy outcome was determined by linking the mother’s Civil
Registration Number to the Medical Birth Registry and the National Hospital Discharge Register. Of 97,903 eligible
pregnancies, 4,443 ended in SAB between 5 and 20 completed gestational weeks, inclusive. Letigen use was reported for
565 pregnancies. Cox regression models accounting for left truncation were fit to estimate the effect of pre-conception and
early pregnancy Letigen use on SAB.
Principal Findings: The estimated maternal age-adjusted hazard ratio for SAB was 1.1 (95% confidence interval 0.8–1.6) for
any periconceptional Letigen use compared to no periconceptional use.
Conclusions: Although Letigen has high levels of caffeine (the recommended 3 pills/day are approximately equivalent to
caffeine from 6 cups of coffee), periconceptional use does not appear to be associated with an appreciably increased hazard
of clinically recognized SAB.
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Introduction
Early gestation is a critical time in fetal development when
women may be unaware they are pregnant and therefore may use
medications, such as diet drugs, that they would not use knowing
they were pregnant. Recently, the obesity epidemic in the United
States has led the Food and Drug Administration (FDA) to weigh
the potential benefits of approving new weight loss drugs against
the potential risks, including the risk that reproductive age women
may use the drugs before becoming aware of pregnancy. In 2012,
the scientific advisory committee to the FDA reversed their 2010
position for one such drug despite concerns that the drug might be
associated with an increased risk of oral clefts [1]. In other
countries, including Denmark, the prevalence of obesity has also
been rising [2], and consequently, reproductive age women may
increasingly turn to prescription or over-the-counter weight loss
products where available. Letigen (NYCOMED, Denmark) was a
prescription diet drug that contained ephedrine and caffeine and
was available in Denmark prior to 2002.
There has been little research on the effects of ephedrine on
pregnancy, but concern over the potential effect of caffeine on
spontaneous abortion (SAB) has resulted in a large but inconclu-
sive literature [3–26]. After considering this literature, the
American College of Obstetricians and Gynecologists published
a committee opinion in 2010 stating the current evidence did not
suggest that consuming less than 200 mg per day of caffeine
during pregnancy increased the risk of SAB, but that the evidence
for higher doses of caffeine was still unclear [27]. Similarly, the
United Kingdom’s Food Standards Agency recommended that
pregnant women limit their caffeine consumption to less than
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200 mg per day due to concerns about fetal growth restriction and
possibly SAB [28]. A number of methodological issues that are
difficult to resolve plague studies of caffeine consumption during
pregnancy and SAB making it difficult to draw conclusions about
the effect of exposure to high doses of caffeine [29–33]. Although
some of these methodological issues do not apply to pre-pregnancy
exposure to caffeine, high exposure to pre-pregnancy caffeine has
also been inconsistently associated with SAB with modestly
elevated effect estimates in some studies [9,12,18,19] but not
others [10,20,22]. Most studies of caffeine focused exclusively on
caffeine from beverages, including coffee, tea, and cola, that
contain other potentially fetotoxic components.
Letigen was a non-beverage source of high doses of caffeine
(200–600 mg/day) that some Danish women used pre-concep-
tionally and inadvertently early in pregnancy. It was banned in
Denmark in 2002 and similar products were banned in the United
States in 2004 due to reports of adverse cardiovascular events
[34,35]. We examine whether periconceptional Letigen use is
associated with SAB in the Danish National Birth Cohort.
Periconceptional Letigen use provides an alternative source of
information on exposure to caffeine and SAB with different
strengths and weaknesses from studies which focus on caffeine
exposure from coffee. Some strengths include that the dose of
caffeine is likely more consistent for women using Letigen
(600 mg/day if used as directed) compared with women who are
exposed to caffeine through coffee, which can be affected by the
type of coffee, how the coffee is prepared, as well as changes in
personal habits [36]. In addition, nausea is unlikely to lead to
mismeasurement of Letigen exposure, but it could affect
measurement of caffeine exposure from coffee [10,30,32,33].
Further, exposure to caffeine from Letigen is not confounded by
other potentially fetotoxic components of coffee although it could
be confounded by ephedrine if ephedrine affects SAB.
Materials and Methods
The Danish National Birth Cohort has been described in detail
elsewhere [37]. Briefly, between March 1, 1996 and November 1,
2002, pregnant women across Denmark were provided informa-
tion about the study during their first prenatal visit. According to a
pilot study, approximately 50% of all pregnant women received an
invitation to participate, and about 60% of those signed the
consent form [37]. The exclusion criteria were not having access to
a telephone, not speaking Danish, and not intending to carry the
pregnancy to term as of the first prenatal visit. A total of 101,051
pregnancies were enrolled.
The Danish National Birth Cohort was approved by the Danish
Scientific Ethics Committee, and this specific study was approved
Figure 1. Study timeline. Timelines based on gestational age showing the risk period for the outcome, the exposure period of interest, the timing
of enrollment, and the exposure period covered by the enrollment forms used in a Danish National Birth Cohort study of spontaneous abortion and
exposure to a diet drug composed of caffeine and ephedrine, 1996–2002.
doi:10.1371/journal.pone.0050372.g001
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Table 1. Summary of counts, fetus-time at risk, and rates per 10,000 for variables stratified on spontaneous abortion (SAB) vs.
other pregnancy outcomes for the Danish National Birth Cohort (1996–2002).
Not SAB SAB
N Fetus-days* N Fetus-days*
Rate of SAB/10,000 fetus-
days
Letigen use{
None 92,930 6,547,875 4,408 108,617 6.6
Pre-conception only 219 17,680 13 274 7.2
Both pre-conception and early pregnancy 270 21,311 17 346 7.8
Early pregnancy only 37 2,725 5 71 17.9
Missing timing 4 327 0 0
Gestational age at entry (completed weeks)
5–8 29,102 2,766,449 2,878 76,695 10.1
9–12 40,260 2,886,894 1,435 30,006 4.9
13–16 18,680 839,147 118 2,465 1.4
17–20 5,418 97,428 12 142 1.2
Maternal age (years)
15–19 987 64,538 40 1,120 6.1
20–24 11,399 818,878 464 11,806 5.6
25–29 38,814 2,797,147 1,609 40,299 5.7
30–34 31,581 2,183,600 1,506 37,775 6.8
35–39 9,756 666,161 683 15,781 10.0
40–46 923 59,594 141 2,527 22.7
Gravidity
No prior pregnancy 30,573 2,215,384 966 25,344 4.3
$1 prior pregnancy 57,061 3,988,842 2,171 55,864 5.4
Missing 5,826 385,692 1,306 28,100
Planned pregnancy
Planned 66,705 4,785,563 2,440 63,180 5.0
Partially planned 11,080 765,877 371 9,349 4.8
Not planned 9,859 654,187 328 8,757 4.9
Missing 5,816 384,291 1,304 28,022
Infertility treatment
Yes 5,700 386,549 167 4,581 4.3
No 81,923 5,817,343 2,972 76,705 5.0
Missing 5,837 386,026 1,304 28,022
Prepregnancy body mass index
Underweight (,18.5) 3,870 272,001 163 4,507 5.9
Normal (18.5–24.9) 58,493 4,138,880 2,076 52,949 5.0
Overweight (25.0–29.9) 16,707 1,182,334 613 15,805 5.1
Obese (. = 30.0) 7,160 510,755 255 7,114 4.9
Missing 7,230 485,948 1,336 28,933
Exercise (hours/week)
None 55,769 3,920,465 1,589 43,290 4.0
.0 to ,2 17,494 1,241,710 626 16,024 5.0
. = 2 to ,4 9,599 697,141 543 13,291 7.6
. = 4 to ,7 3,504 254,635 256 5,895 9.8
. = 7 1,271 91,193 124 2,774 13.2
Missing 5,823 384,774 1,305 28,034
Smoked during pregnancy (cigarette equivalents/day1)
None 67,521 4,781,746 2,342 60,576 4.8
.0 to 10 14,741 1,046,138 569 14,975 5.4
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by the Danish Data Protection Board. All women participating in
the cohort provided written informed consent.
Pregnancy Outcome
Pregnancy outcome was assessed from Danish national regis-
tries, which can be linked using the unique identifier, the Civil
Registration Number. The Medical Birth Registry and the Civil
Registration System were used to obtain data on live and still
births. Other pregnancy outcomes were identified in the National
Hospital Discharge Register, and emigration prior to the end of
pregnancy was determined from the Civil Registration System.
Less than one percent of the study pregnancies could not be linked
to registry data; in these cases, outcome information from the
interviews was used instead [4]. We excluded 34 pregnancies with
unknown outcomes and 142 ectopic and molar pregnancies.
We defined SAB as an involuntary intrauterine loss between
gestational days 35–146, inclusive (i.e. 5–20 completed weeks)
(Figure 1). Primarily, we based gestational age on the National
Hospital Discharge Register, which contained an estimate of
gestational age that was usually based on a sonogram. However,
for 391 pregnancies, we used the last menstrual period (LMP) date
reported on the enrollment form because it seemed reasonable and
the date from the National Hospital Discharge Register was
missing or seemed incorrect. We excluded 124 pregnancies with
missing or erroneous gestational ages, 586 pregnancies enrolled
after the outcome, 172 pregnancies allegedly enrolled prior to
28 days post-LMP, and 2,090 pregnancies enrolled after 146 days
gestation (i.e. no observed time at risk for SAB), yielding a total of
97,903 pregnancies. Eligible multiple births (n = 2,045) were
treated as a single event; we treated the one eligible pregnancy
with discrepant outcomes as a SAB.
Exposure Assessment
The exposure of interest was periconceptional use of Letigen.
Each pill contained 20 mg of ephedrine and 200 mg of caffeine;
the recommended dose was three pills per day [38]. Thus, women
using Letigen as directed ingested caffeine approximately equiv-
alent to drinking five to six cups of coffee a day [39], as well as
ephedrine, and possibly caffeine from other sources. Letigen use
was reported on the enrollment form prior to the pregnancy
outcome. A pregnancy was defined as exposed if any Letigen use
was reported on the enrollment form during the four weeks prior
to the woman’s LMP through 13 completed weeks post-LMP
(n = 565). Twenty-two pregnancies were classified as unexposed
Table 1. Cont.
Not SAB SAB
N Fetus-days* N Fetus-days*
Rate of SAB/10,000 fetus-
days
.10 5,373 376,952 224 5,656 5.9
Missing 5,825 385,082 1,308 28,101
Alcohol during pregnancy (drinks/week)
No drinks 48,727 3,507,924 1,560 41,792 4.4
.0 to ,4 37,112 2,578,283 1,427 36,548 5.5
. = 4 1,823 120,506 152 2,946 12.3
Missing 5,798 383,205 1,304 28,022
Coffee (cups/day)
None 48,693 3,507,238 1,477 40,674 4.2
.0 to ,4 27,519 1,922,961 1,016 25,636 5.2
4 to ,8 8,493 575,907 440 10,171 7.5
. = 8 2,932 198,957 203 4,734 10.0
Missing 5,823 384,855 1,307 28,093
Tea (cups/day)
None 32,583 2,311,375 1,200 31,184 5.1
.0 to ,4 39,427 2,793,264 1,334 34,381 4.7
4 to ,8 11,928 842,605 428 11,156 5.0
. = 8 3,699 257,799 176 4,534 6.7
Missing 5,823 384,875 1,305 28,053
Cola (liters/week)
None 29,967 2,125,366 1,136 30,021 5.3
.0 to ,1 42,896 3,026,527 1,310 33,935 4.3
. = 1 14,758 1,051,921 689 17,210 6.4
Missing 5,839 386,104 1,308 28,142
*Observed fetus days at risk (i.e. time from entry to outcome, censoring, or end of risk period).
{Pre-conception includes the 4 weeks prior to last menstrual period through gestational age 2 completed weeks, early pregnancy includes gestational age 3–13
completed weeks, missing time includes Letigen use during an undefined time.
11 cigarette = 1 cigarette equivalent, 1 cherrot = 2 cigarettes equivalents, 1 cigar = 2 cigarette equivalents, 1 pipe = 1.5 cigarette equivalents.
doi:10.1371/journal.pone.0050372.t001
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despite reported Letigen use because the use predated the
periconceptional period. Four women did not report when they
used Letigen; we assumed they were exposed. We also defined pre-
conception Letigen use as occurring four weeks prior to LMP
through two completed gestational weeks, and early pregnancy use
as occurring from three to 13 completed gestational weeks
(Figure 1).
Classification of exposure status was complicated by the fact
that there were two versions of the enrollment form. On the
original form, used for 65% of the pregnancies, medication type
and timing of use were reported in text fields for the three months
prior to filling out the form (Figure 1). On the revised form, the
participant listed medications consumed and marked boxes to
indicate weeks when the medication was used. The boxes covered
the four weeks prior to the participant’s LMP through enrollment
or 13 completed weeks post-LMP, whichever came first (Figure 1).
Four factors affected Letigen exposure assignment. First, women
enrolled at different times in their pregnancies and therefore
reported Letigen use through different gestational ages (Figure 1).
We assumed that no one took Letigen after they knew they were
pregnant. Given that all women knew they were pregnant at
enrollment, this translated into assuming that no one took Letigen
after enrollment. This assumption seems reasonable because
almost all women specifically stated that they stopped taking
Letigen when they became aware of their pregnancy or clearly
reported cessation of use prior to enrollment. This is also
consistent with a recent United States study of birth defects and
retrospectively-reported weight loss products (including over-the-
counter products) that reported exposure dropping from over 1%
prior to pregnancy to 0.2% by the third month of pregnancy [40].
Table 2. Descriptive statistics by Letigen* exposure status for
the Danish National Birth Cohort (1996–2002).
Non-Letigen* Letigen*
N (%) N (%)
Gestational age at entry (completed weeks)
5–8 31,703 32.6 277 49.0
9–12 41,481 42.6 214 37.9
13–16 18,738 19.3 60 10.6
17–20 5,416 5.6 14 2.5
Maternal age (years)
15–19 1,023 1.1 4 0.7
20–24 11,764 12.1 99 17.5
25–29 40,183 41.3 240 42.5
30–34 32,911 33.8 176 31.2
35–39 10,399 10.7 40 7.1
40–46 1,058 1.1 6 1.1
Gravidity
No prior pregnancy 31,374 32.2 165 29.2
$1 prior pregnancy 58,874 60.5 358 63.4
Missing 7,090 7.3 42 7.4
Planned Pregnancy
Planned 68,859 70.7 286 50.6
Partially planned 11,336 11.6 115 20.4
Not planned 10,065 10.3 122 21.6
Missing 7,078 7.3 42 7.4
Infertility treatment
Yes 5,852 6.0 15 2.7
No 84,388 86.7 507 89.7
Missing 7,098 7.3 43 7.6
Prepregnancy body mass index
Underweight (,18.5) 4,032 4.1 1 0.2
Normal (18.5–24.9) 60,408 62.1 161 28.5
Overweight (25.0–29.9) 17,109 17.6 211 37.3
Obese (. = 30.0) 7,272 7.5 143 25.3
Missing 8,517 8.7 49 8.7
Exercise (hours/week)
None 57,010 58.6 348 61.6
.0 to ,2 18,035 18.5 85 15.0
. = 2 to ,4 10,086 10.4 56 9.9
. = 4 to ,7 3,739 3.8 21 3.7
. = 7 1,382 1.4 13 2.3
Missing 7,086 7.3 42 7.4
Smoked during pregnancy (cigarette equivalents/day{)
None 69,511 71.4 352 62.3
.0 to 10 15,190 15.6 120 21.2
.10 5,546 5.7 51 9.0
Missing 7,091 7.3 42 7.4
Alcohol during pregnancy (drinks/week)
No drinks 49,980 51.3 307 54.3
.0 to ,4 38,336 39.4 203 35.9
. = 4 1,962 2.0 13 2.3
Table 2. Cont.
Non-Letigen* Letigen*
N (%) N (%)
Missing 7,060 7.3 42 7.4
Coffee (cups/day)
None 49,842 51.2 328 58.1
.0 to ,4 28,410 29.2 125 22.1
4 to ,8 8,883 9.1 50 8.8
. = 8 3,115 3.2 20 3.5
Missing 7,088 7.3 42 7.4
Tea (cups/day)
None 33,567 34.5 216 38.2
.0 to ,4 40,532 41.6 229 40.5
4 to ,8 12,300 12.6 56 9.9
. = 8 3,853 4.0 22 3.9
Missing 7,086 7.3 42 7.4
Cola (liters/week)
None 30,976 31.8 127 22.5
.0 to ,1 43,981 45.2 225 39.8
. = 1 15,276 15.7 171 30.3
Missing 7,105 7.3 42 7.4
*Letigen is composed of 20 mg ephedrine and 200 mg caffeine.
{1 cigarette = 1 cigarette equivalent, 1 cherrot = 2 cigarettes equivalents, 1
cigar = 2 cigarette equivalents, 1 pipe = 1.5 cigarette equivalents.
doi:10.1371/journal.pone.0050372.t002
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For each version of the enrollment form, the mean gestational
age at entry was ten (standard deviation (SD) three) weeks.
However, the two forms referred to different timeframes (Figure 1).
The exposure period of interest was covered by the checkbox
enrollment form and the text-based form for women enrolling by
eight weeks. However, women who used the text-based form and
enrolled after eight completed weeks were asked only about part of
this timeframe. In practice, Letigen users who completed the text-
based form and enrolled late tended to report medication usage
covering the entire timeframe of interest (i.e. usage more than
three months prior to enrollment). However, women who used the
text-based enrollment form and did not report Letigen use might
be mistakenly classified as unexposed if they used Letigen pre-
conceptionally and enrolled late. We examined this issue
analytically by performing sub-analyses where we excluded late
enrollers or stratified on the version of the form used.
The third issue was that the timing of Letigen use was often
reported vaguely on the text-based form. We reviewed each text
field individually and developed rules regarding the timing of
exposure for commonly used phrases (e.g., six days in early
September was assumed to be the middle six days in the first ten
days of the month). Because we assessed broad exposure windows,
most women were clearly exposed or unexposed periconception-
ally, despite nonspecific responses.
The final challenge was that women reported Letigen use
relative to self-reported LMP, which was not always consistent
with the estimated LMP based on the National Hospital Discharge
Register. For 87% of the women, the dates were within a week of
each other (30% were identical) so reports pertained to the
relevant timeframe despite minor date discrepancies. Of the 1,452
pregnancies where LMP dates differed by more than four
completed weeks and the National Hospital Discharge Register
date was determined to be the best estimate, 11 women reported
using Letigen. Their exposure status did not change regardless of
the gestational age definition used. Some of the 1,441 women who
were classified as unexposed might have been exposed if they had
reported on the relevant timeframe only, but the number is likely
to be small. We addressed this uncertainty through a sensitivity
analysis excluding pregnancies for which gestational age was based
on the National Hospital Discharge Register and for which the
self-reported and Register-based LMPs differed by more than four
completed weeks.
Other Variables
Maternal age at LMP was calculated using birth date from the
Civil Registration System. Information on all other covariates was
collected through telephone interviews. Of the 97,903 pregnancies
in this study, 7,094 were never interviewed. Of the women
Table 3. Summary statistics for the number of weeks that Letigen* was used at least once among women in the Danish National
Birth Cohort (1996–2002).
Weeks
Timeframe of use{ N Mean SD Minimum Maximum
Total eligible time 561 6.3 3.3 1 16
Pre-conception only 232 4.1 1.9 1 7
Both pre-conception and early pregnancy 287 8.7 2.5 2 16
Pre-conception time 6.0 1.9 1 7
Early pregnancy time 2.7 1.5 1 9
Early pregnancy only 42 2.3 1.5 1 8
*Letigen is composed of 20 mg ephedrine and 200 mg caffeine.
{Total eligible time includes the 4 weeks prior to last menstrual period through gestational age 13 completed weeks, pre-conception includes the 4 weeks prior to last
menstrual period through gestational age 2 completed weeks, early pregnancy includes gestational age 3–13 completed weeks.
Abbreviations: SD, standard deviation.
doi:10.1371/journal.pone.0050372.t003
Table 4. Unadjusted and age-adjusted hazard ratios and 95% confidence intervals for the association between Letigen* use and
spontaneous abortion (SAB) in the Danish National Birth Cohort (1996–2002).
Unadjusted Age adjusted{
Timeframe of exposure1 SAB Fetus-days$ HR (95% CI) HR (95% CI)
None 4,408 6,656,492 1.0 ref 1.0 ref
Pre-conception only 13 17,954 1.0 0.6; 1.6 1.0 0.6; 1.7
Both pre-conception and early pregnancy 17 21,657 1.0 0.6; 1.7 1.1 0.7; 1.7
Early pregnancy only 5 2,796 2.6 1.1; 6.5 2.7 1.1; 6.6
*Letigen is composed of 20 mg ephedrine and 200 mg caffeine.
{Adjusted for maternal age using the following categories: 15–19, 20–24, 30–34, 35–39, 40–46 with 25–29 as the referent.
1Pre-conception includes the 4 weeks prior to last menstrual period through gestational age 2 completed weeks; early pregnancy includes gestational age 3–13
completed weeks.
$Observed fetus days at risk (i.e. time from entry to outcome, censoring, or end of risk period).
Abbreviations: HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0050372.t004
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contacted for the first pregnancy interview, 3,144 were no longer
pregnant and therefore were not interviewed at that time. The
mean gestational age at interview for women who were still
pregnant was 16 completed weeks (range 5–37 weeks). Approx-
imately 80% of the women who were no longer pregnant agreed to
participate in an alternative interview, which for our purposes, was
comparable to the pregnancy interview.
Statistical Analyses
We fit Cox regression models accounting for left truncation to
estimate the effect of Letigen on SAB. We used gestational age in
days with entry into observation defined as enrollment in the
study. We employed the robust Lin and Wei confidence interval
option in SAS 9.2 (Cary, North Carolina) to account for the fact
that some women (n = 8,099) contributed more than one
pregnancy to the study. Pregnancies that ended in an induced
abortion (n = 425) and where the mother died (n = 3) or emigrated
(n = 48) prior to 20 completed weeks gestation were censored.
We considered the following potential confounders: maternal
age, pre-pregnancy body mass index (BMI), exercise, smoking,
alcohol consumption, and consumption of caffeine from beverag-
es. Although these factors could conceivably be confounders or
proxies for confounders, none substantially changed the effect-
measure estimates for Letigen separately or as a group (,3%
change in estimate). Given that a higher proportion of women
with SABs did not have interviews compared with women with
other pregnancy outcomes (29% vs. 6%) and the fact that none of
the other covariates appeared to confound the effect-measure
estimate considerably, we opted to report the results for the model
adjusted for maternal age only. This allowed us to include all
eligible pregnancies.
Results
Table 1 provides counts and observed fetus-time at risk for the
study population by outcome. As expected, older women were
more likely to have a pregnancy loss, and as previously published,
SAB was associated with higher coffee consumption during
pregnancy [4]. Letigen use was strongly associated with higher
prepregnancy BMI (Table 2). In addition, Letigen users tended to
drink more cola than non-users, but the two groups were similar
on all other factors including reported coffee consumption and tea
consumption. Among Letigen users, the average number of
gestational weeks with any Letigen use was 6 (SD 3) during the
exposure period interest (Table 3). Most Letigen use was reported
during the pre-conception period rather than early pregnancy.
The maternal age-adjusted hazard ratio (HR) for any Letigen
use compared to no use was 1.1 (0.8–1.6). Table 4 shows
unadjusted and age-adjusted HRs from models examining Letigen
use during different timeframes. Only women who used Letigen
during early pregnancy exclusively had an elevated hazard
(adjusted HR 2.7; 1.6–6.6), but there were only five SABs exposed
to Letigen during this timeframe.
We conducted additional analyses to examine the sensitivity of
our results to possible misclassification of Letigen use. First, we
excluded women who used the text-based form and enrolled after
eight weeks gestation; the age-adjusted HR did not change
substantially from that of the complete study population (1.2; 0.8–
1.7). Excluding all women who enrolled after eight weeks
gestation, regardless of which enrollment form was used, also did
not change the estimate (1.1; 0.8–1.6). Limiting to pregnancies
dated by self-reported LMP (i.e. LMP from the enrollment form
where medication use was reported) or where the Register
estimated LMP differed from the self-reported LMP by fewer
than five weeks yielded an age-adjusted HR of 1.2 (0.9–1.7).
Finally, restricting our analysis to nulligravida women yielded in
an age-adjusted HR of 1.1 (0.5–2.4).
Discussion
Periconceptional Letigen use is not appreciably associated with
SAB in this study. Although pre-pregnancy Letigen use showed
little or no association with SAB, early pregnancy use was
associated with an elevated HR. However, the elevated HR was
based on only five exposed SABs. If Letigen were causally related
to SAB when taken in early pregnancy, it would be expected to be
harmful for any exposed pregnancy, whether or not the woman
also took it prior to conception. However, women exposed during
both periods showed no elevated risk. Further, the effect measure
estimate for Letigen use during early pregnancy only may be
confounded. Although adjusting for measured potential confound-
ers did not change the estimate meaningfully, it is possible that
women who began using Letigen after conception may have been
more likely to participate in unmeasured behaviors that increase
the hazard of SAB.
Some assumptions were made to determine exposure status
during the timeframe of interest; to the degree that we could test
these assumptions, the overall effect-measure estimates appeared
robust. We accounted for left truncation analytically. However,
this approach assumes that the pregnancies under observation at a
given gestational age are representative of all pregnancies at that
gestational age. Bias could be introduced if this was not the case,
especially if entry was associated with the exposure [41]. Further,
gestational age may be less accurate for SABs because live births
are more likely to have a sonogram. However, previous work
suggests bias due to differential accuracy in gestational age by
outcome is likely to be small given realistic assumptions about the
magnitude of these differences [42].
Letigen was composed of ephedrine and caffeine. To our
knowledge, no prior studies looked at weight loss products in
relation to SAB. A National Birth Defects Prevention Study
reported that periconceptional use of weight loss products
containing ephedra (a botanical source of the alkaloid ephedrine)
was associated with increased risk for some birth defects although
the effect-measure estimates were imprecise [40]. While the
relation between diet drugs and SAB has not been studied, an
extensive literature addresses caffeine and SAB [3–26]. Opinions
published in both the United States and the United Kingdom
could not reach consensus regarding the relation between
consumption of high doses of caffeine during pregnancy and
SAB, but both recommended women limit their consumption to
less than 200 mg per day [27,28].
High coffee consumption (greater than 4 cups per day) during
pregnancy is associated with late SAB in the Danish National Birth
Cohort [4], which contrasts with the results for periconceptional
Letigen consumption. The results may differ for several reasons.
First, the study of coffee and SAB only included late losses because
pregnancies interviewed after the outcome were excluded to avoid
recall bias. In contrast, earlier losses were included for pericon-
ceptional Letigen use, which was reported at enrollment,
precluding recall bias. Second, although both coffee and Letigen
contain caffeine, coffee also contains other substances that may
affect SAB. Additionally, caffeine levels from coffee were likely
based on coffee consumption at the time of the interview, which
probably represented average daily exposure after becoming
aware of pregnancy. In contrast, while the dose of caffeine may be
consistent for women taking Letigen (ranging from 200 to 600 mg
of caffeine depending on the number of pills consumed), the timing
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of use during early pregnancy may have been brief or sporadic.
Letigen use was reported for an average of less than three weeks
during the exposure period of interest. It is possible that regular
exposure to high doses of caffeine affects SAB but sporadic
exposure to high doses does not.
One concern in studies of caffeine consumption during
pregnancy is that pregnancy induced nausea can lead to food
and beverage aversions, while lack of nausea is strongly associated
with an increased risk of SAB. As a result, observed associations
between caffeine and SAB could be spurious [10,30,32,33]. An
advantage of assessing pre-pregnancy caffeine consumption is that
the exposure predates the onset of nausea so any observed
association is not a result of nausea’s effect on caffeine
consumption. However, pre-conception caffeine exposure cannot
be generalized to caffeine exposure during pregnancy because
effects may differ during different developmental periods. In
addition, pre-conception caffeine exposure may have an effect on
early pregnancy loss (,5 completed weeks), but not on clinically
recognized SAB.
Women tended to cease using Letigen once they became aware
of their pregnancy. Therefore, there was limited early pregnancy
exposure in this study, but Letigen users were exposed to caffeine
for longer periods prior to conception. Researchers examining pre-
pregnancy (beverage) caffeine consumption and SAB
[9,10,12,14,18–20,22] reported inconsistent results even for high
levels of caffeine. However, the effect-measure estimates for high
caffeine intake prior to pregnancy are smaller than estimates for
high caffeine intake during pregnancy in studies that looked at
both periods. We also found a stronger association between SAB
and Letigen use during early pregnancy compared to pre-
conceptional use although relatively few women consumed
Letigen in early pregnancy exclusively. The association between
SAB and Letigen use during both periods was essentially null.
We did not have adequate data to evaluate whether caffeine
from other medications might confound the association between
Letigen and SAB. Some painkillers and migraine medications that
contained caffeine were available during the study period. These
types of drugs were likely used sporadically and had much lower
caffeine content (50–100 mg/pill) than Letigen (200 mg/pill).
Therefore, it seems likely that few study participants were regularly
exposed to high doses of caffeine from other medications.
We evaluated whether caffeine from beverages could confound
this study. Although women were asked about coffee, tea, and cola
consumption, the questions were not anchored to a specific time
period. We considered whether reported caffeine intake from
beverages could approximate periconceptional caffeine consump-
tion as well as whether caffeine from beverages might be an
intermediate between Letigen and SAB. If the latter were true,
adjustment for beverage caffeine would be inappropriate. Only
cola consumption appeared to be associated with Letigen use in
our data. High prior cola consumption could contribute to obesity,
which could lead to Letigen use, or alternatively, obesity could
lead to both Letigen use and diet cola consumption. In both of
these scenarios cola could be a confounder if caffeine from cola
caused SAB. Adjustment for cola consumption did not change the
results appreciably (1.0; 0.7–1.5) although residual confounding
due to imprecise measurement of cola consumption is possible.
In the Danish National Birth Cohort, periconceptional use of a
diet pill containing ephedrine and caffeine does not appear to be
appreciably associated with clinically recognized SAB.
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